Overview
Services
Volunteer
Values
Careers
Contact
     
Education
Forums
Newsletter
 
 
Overview
Bioethic aspects       
Phase I clinical process for:
- Generic drugs     
- New medicines   
Current clinical studies
Participation form                 
Information                       
 
 
 
 
Process of pharmaceutical development for generic medication.



A new medication drug has two names: one corresponding to its chemical denomination and the other one to its brand name. Both are chosen and attributed by the manufacturer. The brand name is exclusive and can not be used by any other company.






When a pharmaceutical company finds a new medication and believes in its future - called at this stage a drug or a chemical entity - it applies for a patent and obtains an exclusivity for 20 years duration (according to the countries). This gives to it the time to manufacture the medication and to test it in animals and humans before to be able to put it on the market. The development duration of the medication determines the price. The longer the medication needs time to be developed the more expensive it will be.


In fact, among 10.000 of chemical entities found having a potential pharmacological activity, just one or two (very rare) are probably put on the market.



When the patent expires, the manufacturer looses the exclusivity and other companies can make the product and sale it under a generic name. Therefore a medication has one brand name but can has different generic names.






The lawful agencies (ex : Health Canada, FDA, EMEA, etc.) request that the two products (brand and generic) are equivalent and demonstrate the same pharmacological behavior. Since the product is tested on humans, we talk about a bioequivalence testing.
The lawful agencies do not make any difference when inspecting the pharmaceutical companies manufacturing innovator products or generics, all of them must comply with the applicable standards.






No medication can be sold without obtaining the approval of the lawful agencies of the country where the product will be commercialized.
The Phase I clinical process and the bioequivalence studies involve usually the healthy volunteers. Dear Volunteers, if you want to know more about the process of developing and marketing a medication, please click on the following link << FAQ/Library>> and should you have any question, do not hesitate to contact us.
What about the quality of generic medications?



o

Both medications (brand and generic) contain the same active ingredient(s) and have to demonstrate a comparative pharmacological behavior (absorption, metabolization, distribution and elimination).



o

The generic product may have a different color or form in comparison with the brand one but this does not affect at all the therapeutic effect of the medication. A patient can switch from one to the other without experiencing any difference in the control of the illness.
Why are generic products manufactured and distributed?



o

Given that the quality is the same, a physician can prescribe the brand name or the generic, but the pharmacist suggest to the patient to buy the generic product without needing the Doctor's approval, except when the patient wants his physician's opinion.




o


In the majority of the cases, the RAMQ and certain private insurance companies refund only the price of the generic form. Indeed, generic drugs are extremely less expensive, not because they are less effective but because they undergo a less long time of manufacturing and thus less expensive process of pharmaceutical development.
                      Go Back

©2006, ALS Inc. All rights reserved